Efficacy and Safety of Dual Therapy With Dolutegravir/Lamivudine in Treatment-naive Persons With CD4 Counts <200/mm3: 48-Week Results of the DOLCE Study. (academic.oup.com)

Authors: Figueroa MI … Cahn P Journal: Clinical Infectious Diseases Published: 2026-02-09 DOI: https://doi.org/10.1093/cid/ciaf415